N-Terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], Aid Differentiation of E75-TCR(+)CD8(+) Cells to Perforin-positive Cells

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Matsueda, S en
dc.contributor.author Gao, H en
dc.contributor.author Efferson, CL en
dc.contributor.author Tsuda, N en
dc.contributor.author Ishiyama, S en
dc.contributor.author Li, YF en
dc.contributor.author Ioannides, MG en
dc.contributor.author Fisk, B en
dc.contributor.author Peoples, GE en
dc.contributor.author Ioannides, CG en
dc.date.accessioned 2014-03-01T01:58:56Z
dc.date.available 2014-03-01T01:58:56Z
dc.date.issued 2009 en
dc.identifier.issn 0250-7005 en
dc.identifier.uri https://dspace.lib.ntua.gr/xmlui/handle/123456789/28783
dc.subject HER-2 en
dc.subject helper effect en
dc.subject AE-37 en
dc.subject AE-47 en
dc.subject p776 en
dc.subject F7 en
dc.subject perforin en
dc.subject E75 en
dc.subject cancer vaccines en
dc.subject high-affinity CD8(+) cells en
dc.subject.classification Oncology en
dc.subject.other BREAST-CANCER PATIENTS en
dc.subject.other CLASS-II MOLECULES en
dc.subject.other INVARIANT CHAIN en
dc.subject.other CLINICAL-TRIAL en
dc.subject.other LYMPH-NODE en
dc.subject.other RESPONSES en
dc.subject.other EPITOPES en
dc.subject.other VACCINES en
dc.subject.other COMPLEX en
dc.subject.other TUMOR en
dc.title N-Terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], Aid Differentiation of E75-TCR(+)CD8(+) Cells to Perforin-positive Cells en
heal.type journalArticle en
heal.language English en
heal.publicationDate 2009 en
heal.abstract The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776788), respectively, help differentiation of E75-TCR(+)CD8(+) cells. Activation was quantified in terms of proliferation of E75-TCR(+)CD8(+) cells expressing high, medium and low density amounts of the specific TCR. Differentiation to functional CD8(+) cells was quantified as induction of Perforin (Perf), the lytic-enzyme which mediates the effector function of CD8(+) cells, in E75-TCR(+)CD8(+) cells. Peripheral blood mononuclear cells (PBMCs) of 3 patients activated with E75(+)AE-37 and E75(+)AE-47 more greatly increased the number of E75-TCRHi CD8(+)Perf(+) cells than PBMCs activated by AE-47 alone or AE-47(+) E75. E75 plus cytokines and cytokines alone activated more E75-TCRLow cells than did AE-37 and AE-47. E75(+) AE-37 and AE-37 also induced differentiation of small- and medium-size activated CD8(+) cells from BRC ascites, in allogeneic activation, to Perf(+) cells. Preferential differentiation of E75-TCR(+)CD8(+)Perf(+) cells in distinct patients by AE-37 and AE-47 indicates that cancer vaccines will benefit from such correct individual and disease-associated help. Additional studies using the natural peptides p776 and F7 are needed to understand whether the LRMK-(Ava) tetra-, or pentamer augments or inhibits differentiation of CD8(+) cells, compared with native, natural HER-2 peptides and/or protects CD8(+) cells activated by E75 and by other HLA-I bound peptides from death. Our findings also develop a model for uniform quantification of differentiated CD8(+) effectors. en
heal.journalName ANTICANCER RESEARCH en
dc.identifier.isi ISI:000268104100002 en
dc.identifier.volume 29 en
dc.identifier.issue 7 en
dc.identifier.spage 2427 en
dc.identifier.epage 2435 en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record